Background
Methods
Study design and patient population
Definitions
-
received intravenous therapy at home; received wound care or specialized nursing care through a healthcare agency, family or friends; or self-administered intravenous medical therapy in the 30-day period before the onset of the infection;
-
attended a hospital or hemodialysis clinic, or received intravenous chemotherapy in the previous 30 days;
-
hospitalized in an acute care hospital for 2 or more days in the previous 90 days;
-
resided in a nursing home or long-term care facility.
Statistical analysis
Results
Patients’ characteristics | TOTAL (n = 1035) | CAI and HCAI (n = 718) | HAI (n = 317) |
p-value
|
---|---|---|---|---|
Male sex, n (%) | 506 (49) | 344 (48) | 162 (51) | 0.343* |
Age, mean (SD) | 65 (20) | 65 (20) | 64 (19) | 0.405&
|
SAPSII, mean (SD) | 29 (13) | 29 (12) | 30 (13) | 0.962&
|
Severity of infection, n (%) | 0.922* | |||
Localized infection without SIRS | 281 (27) | 195 (27) | 86 (27) | |
Sepsis | 364 (35) | 251 (35) | 113 (36) | |
Severe sepsis | 296 (29) | 209 (29) | 87 (27) | |
Septic shock | 94 (9) | 63 (9) | 31 (10) | |
Previous comorbidities, n (%) | 671 (65) | 460 (64) | 211 (67) | 0.438* |
Chronic hepatic disease, n (%) | 22 (2) | 18 (3) | 4 (1) | 0.822$
|
Chronic renal disease, n (%) | 149 (14) | 94 (13) | 55 (17) | 0.072* |
Chronic heart failure, n (%) | 74 (7) | 46 (6) | 28 (9) | 0.163* |
Chronic respiratory disease, n (%) | 66 (6) | 52 (7) | 14 (4) | 0.086* |
Hematologic disease, n (%) | 60 (6) | 35 (5) | 25 (8) | 0.056* |
Cancer, n (%) | 45 (4) | 26 (4) | 19 (6) | 0.084* |
Diabetes, n (%) | 204 (20) | 144 (20) | 60 (19) | 0.674* |
Atherosclerotic disease, n (%) | 242 (23) | 168 (23) | 74 (23) | 0.985* |
Immunosuppression, n (%) | 221 (21) | 137 (19) | 84 (27) | 0.007* |
Karnofsky index<70, n (%) | 319 (31) | 227 (32) | 92 (29) | 0.405* |
Hospitalization in the previous year, n (%) | 413 (40) | 239 (33) | 174 (55) | <0.001* |
Previous antibiotic therapy, n (%) | 367 (36) | 137 (19) | 230 (73) | <0.001* |
Hospital mortality, n (%) | 138 (13) | 79 (11) | 59 (19) | 0.001* |
Variables | Total, n (%) n=718 | Microbiological documentation, n (%) n=439 | MDR, n (%) n=123 | Crude OR | p-value | MDR-GN, n (%) n=104 | Crude OR | p-value | ESKAPE pathogens, n(%) n=41 | Crude OR | p-value |
---|---|---|---|---|---|---|---|---|---|---|---|
Age | 1.6* | <0.001 | 1.5* | 0.009 | 1.3* | 0.170 | |||||
≤60 years | 271 (38) | 166 (38) | 33 (27) | 30 (28) | 13 (32) | ||||||
61-80 years | 250 (35) | 157 (36) | 44 (36) | 37 (36) | 13 (32) | ||||||
>80 years | 197 (27) | 116 (26) | 46 (37) | 37 (36) | 15 (36) | ||||||
Male sex | 344 (48) | 203 (46) | 56 (46) | 1.1 | 0.656 | 45 (43) | 0.9 | 0.542 | 21 (51) | 1.2 | 0.503 |
Previous antibiotic therapy | 137 (19) | 94 (21) | 38 (31) | 1.9 | 0.009 | 30 (29) | 1.7 | 0.033 | 20 (49) | 4.2 | <0.001 |
Hospitalization in the previous year (4 months - 1 year) | 146 (20) | 102 (23) | 37 (30) | 2.1 | 0.006 | 29 (28) | 1.8 | 0.031 | 14 (34) | 3.3 | 0.003 |
Immunosupression (not meeting criteria of HCAI) | 113 (16) | 81 (19) | 25 (20) | 1.1 | 0.685 | 24 (23) | 1.5 | 0.116 | 10 (24) | 1.5 | 0.306 |
Chronic hepatic disease | 18 (3) | 14(3) | 4 (3) | 0.9 | 0.818 | 3 (3) | 0.9 | 0.829 | 2 (5) | 1.7 | 0.522 |
Chronic heart failure | 46 (6) | 27 (6) | 13 (11) | 2.5 | 0.026 | 11 (11) | 2.3 | 0.038 | 2 (5) | 0.8 | 0.723 |
Chronic respiratory disease | 52 (7) | 30 (7) | 13 (11) | 2.2 | 0.056 | 11 (11) | 1.9 | 0.093 | 4 (10) | 1.6 | 0.439 |
Chronic haematologic disease | 35 (5) | 29 (7) | 8 (7) | 1.0 | 0.945 | 5 (5) | 0.7 | 0.444 | 5 (12) | 2.2 | 0.139 |
Cancer (not meeting criteria of HCAI) | 10 (1) | 6 (1) | 2 (2) | 1.5 | 0.666 | 2 (2) | 1.6 | 0.578 | 0 (0) | ||
Diabetes | 144 (20) | 96 (22) | 32 (26) | 1.3 | 0.291 | 27 (26) | 1.4 | 0.239 | 11 (27) | 1.4 | 0.421 |
Atherosclerosis | 168 (23) | 105 (24) | 40 (33) | 1.8 | 0.017 | 32 (31) | 1.6 | 0.069 | 13 (32) | 1.5 | 0.222 |
Karnofsky index<70 | 227 (32) | 149 (34) | 57 (46) | 1.8 | 0.006 | 44 (42) | 1.6 | 0.046 | 22 (54) | 2.5 | 0.006 |
Variables | MDR, n (%) n = 123 | Adjusted OR | CI95%
| p-value | MDR Gram negatives, n (%) n = 104 | Adjusted OR | CI95%
| p-value | ESKAPE pathogens, n(%) n= 41 | Adjusted OR | CI95%
| p-value |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Age | 1.7 | 1.3-2.3 | 0.001 | 1.5 | 1.1-2.1 | 0.009 | ||||||
≤60 years | 33 (27) | 30 (28) | 13 (32) | |||||||||
61-80 years | 44 (36) | 37 (36) | 13 (32) | |||||||||
>80 years | 46 (37) | 37 (36) | 15 (36) | |||||||||
Previous antibiotic therapy | 38 (31) | 30 (29) | 20 (49) | 7.2 | 3.1-17.0 | <0.001 | ||||||
Hospitalization in the previous year (4 months - 1 year) | 37 (30) | 2.0 | 1.2-3.4 | 0.008 | 29 (28) | 1.7 | 1.0-3.0 | 0.048 | 14 (34) | |||
Karnofsky index<70 | 57 (46) | 44 (42) | 22 (54) | 3.7 | 1.6-8.6 | 0.003 |
Variables | MDR, | Non-MDR, | Non- MDRvsMDR, | MDR-GN | Non-MDR-GN, | Non-MDR-GNvsMDR-GN, | ESKAPE pathogens, | Non-ESKAPE pathogens, | Non-ESKAPEvsESKAPE, |
---|---|---|---|---|---|---|---|---|---|
n (%) | n (%) | p Value | n (%) | n (%) | p Value | n (%) | n (%) | p value | |
Inadequate ATB therapy | 57 (46) | 19 (7) | <0.001* | 46 (44) | 30 (10) | <0.001* | 25 (61) | 51 (15) | <0.001* |
Hospital LOS, median (IQR) | 10 (7–17) | 10 (7–16) | 0.944#
| 10 (7–15) | 10 (7–17) | 0.487#
| 11 (8–15) | 10 (7–17) | 0.280#
|
SAPS II, mean (SD) | 32 (13) | 30 (13) | 0.171&
| 31 (13) | 30 (13) | 0.428&
| 32 (17) | 30 (12) | 0.373&
|
Hospital mortality | 19 (15) | 31 (12) | 0.280* | 13 (13) | 37 (13) | 0.928* | 9 (22) | 41 (12) | 0.062* |